U.S. Markets close in 4 hrs 19 mins

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin, Ph.D., Chief Executive Officer and Director of Replimune, will participate in fireside chats and host investor meetings at the following two conferences.

Guggenheim Healthcare Talks Forum – Oncology Day
Date: Thursday, February 14, 2019
Presentation Time: 1:30 pm ET
Location: St. Regis in New York, NY

8th Annual SVB Leerink Global Healthcare Conference
Date: Thursday, February 28, 2019
Presentation Time: 2:00 pm ET
Location: Lotte New York Palace in New York, NY

About Replimune

Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of “oncolytic immunotherapies” for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action. For more information, please visit www.replimune.com.

Replimune Contact
Pamela Esposito, Ph.D.
Replimune Group Inc.
617.233.6988
pamela@replimune.com

Investor Inquiries
Chris Brinzey
Westwicke Partners, an ICR Company
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Verge Scientific Communications
917.548.1582
agoldenberg@vergescientific.com